Galectin Therapeutics Inc. (NASDAQ:GALT)

CAPS Rating: 1 out of 5

A development stage pharmaceutical company engaged in the discovery, development and commercialization of carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases.

Results 1 - 9 of 9

Recs

2
Member Avatar zzlangerhans (99.80) Submitted: 2/28/2015 7:23:09 PM : Outperform Start Price: $3.46 GALT Score: -3.02

I've been doing well on CAPS playing the ups and downs of Galectin, a former cultish favorite that has lost its sheep after overhyping expectations for the phase I trial of GR-MD-02 for NASH. I'm starting to like the prospects of the slimmed down stock as it approaches the the recent floor of 3.2 just around the time the company has likely submitted an SPA application for the NASH-CX phase II trial of GR-MD-02 in NASH with cirrhosis and portal hypertension. I haven't forgotten Galectin's past flings with misrepresentations and paid promotion but these days the company is behaving in a much more restrained fashion. Has management turned over a new leaf? I wouldn't bet the farm here but I see this as a reasonable risk/reward scenario once the price gets below 3.3.

Recs

0
Member Avatar pchop12316 (58.26) Submitted: 2/26/2015 5:23:09 PM : Outperform Start Price: $3.46 GALT Score: -2.95

intrinsic value continues

Recs

0
Member Avatar spirts (< 20) Submitted: 12/24/2014 6:40:07 AM : Outperform Start Price: $3.04 GALT Score: +8.95

GALT

Recs

0
Member Avatar Allstar13913 (99.82) Submitted: 9/11/2014 10:09:44 PM : Underperform Start Price: $5.59 GALT Score: +45.66

Stock Promoter Pump and dump that uses Redchip.com to fool retail investors into buying. The company was formerly bankrupt and is a con job. Don't buy.

Recs

0
Member Avatar superstar (99.61) Submitted: 7/30/2014 11:21:17 AM : Outperform Start Price: $7.15 GALT Score: -60.18

I liked the GALT statement issued on its GR-MD-02 Development Program. The company believes the market misinterpreted positive clinical data.

Recs

0
Member Avatar newt1322 (< 20) Submitted: 9/16/2013 11:54:30 AM : Outperform Start Price: $10.35 GALT Score: -91.48

galt is 20 years ahead of everyone else due to the smart move of bringing the lead russian scientist over and securing his 20-25 years of research and folding it into what they knew about the molecules.

Recs

0
Member Avatar adi101 (90.06) Submitted: 8/4/2013 1:42:20 PM : Outperform Start Price: $6.00 GALT Score: -68.12



Specilative

Recs

3
Member Avatar BuffettJunior1 (97.82) Submitted: 6/2/2011 4:58:08 PM : Underperform Start Price: $7.74 GALT Score: +119.34

The only thing this company is good at is burning money. Over the past 10 years the company hasn't made a dime. I still don't understand how this garbage stock has a market cap of 100 million.

Recs

0
Member Avatar Biotoday (48.19) Submitted: 10/7/2010 11:26:17 AM : Outperform Start Price: $4.33 GALT Score: -104.91

From Accredited Investor grapevine

Results 1 - 9 of 9

Featured Broker Partners


Advertisement